# Double-dose Valsartan Monotherapy in Hypertension Treatment: an Effectiveness and Safety Evaluation in Chinese Patients.

> **NCT01541189** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 200 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Valsartan

## Key facts

- **NCT ID:** NCT01541189
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02
- **Primary completion:** 2013-01
- **Final completion:** 2013-01
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2017-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01541189

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01541189, "Double-dose Valsartan Monotherapy in Hypertension Treatment: an Effectiveness and Safety Evaluation in Chinese Patients.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01541189. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*